The family office has offices in Belgium and Luxembourg. The firm makes equity investments in life science companies, typically at the Series A stage or later; the firm allocates a total of EUR 3-15 million over the life of an investment. The majority of the firm’s investments are in Europe (~75%) and the rest are in the US.
In the life science sector, the firm invests in medical applications (therapeutics, diagnostics, and medical devices), digital health, life science services and tools, and agtech / food tech. For therapeutics companies, the firm only invests in companies with assets that have obtained data from in-human clinical trials (at minimum, human safety data is required). For medtech or diagnostic companies, the product must be no more than 1 year from commercialization. For digital health companies, the firm prefers to see companies that have market traction, with 2-3M EUR in revenue. In life science tools, the firm is particularly interested in companies with technologies in the -omics space, drug design platforms, or relating to data. The firm invests broadly in the life science field, but has a specific interest in technologies at the intersection between the healthcare and food industries, including nutraceuticals and the microbiome.
The firm is a hands-on investor that prefers to take a board seat and work closely with management. The firm prefers to invest as part of a strong syndicate that includes experienced investors with whom the firm has pre-existing connections.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply